US NUCLEAR CORP. Annual Nonoperating Income (Expense) in USD from 2013 to 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Us Nuclear Corp. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2013 to 2023.
  • Us Nuclear Corp. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$41.7K, a 93.9% increase year-over-year.
  • Us Nuclear Corp. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was -$587K, a 64.1% increase year-over-year.
  • Us Nuclear Corp. annual Nonoperating Income (Expense) for 2023 was -$1.79M, a 228% decline from 2022.
  • Us Nuclear Corp. annual Nonoperating Income (Expense) for 2022 was -$547K, a 6.27% decline from 2021.
  • Us Nuclear Corp. annual Nonoperating Income (Expense) for 2021 was -$514K, a 64.6% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$1.79M -$1.25M -228% Jan 1, 2023 Dec 31, 2023 10-K 2024-05-10
2022 -$547K -$32.3K -6.27% Jan 1, 2022 Dec 31, 2022 10-K 2024-05-10
2021 -$514K +$940K +64.6% Jan 1, 2021 Dec 31, 2021 10-K 2023-05-12
2020 -$1.45M -$753K -107% Jan 1, 2020 Dec 31, 2020 10-K 2022-04-15
2019 -$701K -$685K -4425% Jan 1, 2019 Dec 31, 2019 10-K 2021-07-29
2018 -$15.5K +$8.82K +36.3% Jan 1, 2018 Dec 31, 2018 10-K 2020-07-02
2017 -$24.3K -$3.48K -16.7% Jan 1, 2017 Dec 31, 2017 10-K 2019-04-17
2016 -$20.8K +$4.06K +16.3% Jan 1, 2016 Dec 31, 2016 10-K 2018-04-17
2015 -$24.9K -$179K -116% Jan 1, 2015 Dec 31, 2015 10-K 2017-04-17
2014 $154K -$116K -43% Jan 1, 2014 Dec 31, 2014 10-K 2015-04-15
2013 $269K Jan 1, 2013 Dec 31, 2013 10-K 2015-04-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.